Skip to main content
. Author manuscript; available in PMC: 2024 Oct 11.
Published before final editing as: Lancet Infect Dis. 2024 Sep 26:S1473-3099(24)00512-7. doi: 10.1016/S1473-3099(24)00512-7

Figure 1. Potential regimens based on individual drug rankings.

Figure 1

B = bedaquiline, H = isoniazid, L = linezolid, M = moxifloxacin, O = DprE1 inhibitor, Pa = pretomanid, Rb = rifabutin, S = sutezolid, AlpE = alpibectir/ethionamide, Z = pyrazinamide, R = rifampicin (high dose), Fq = fluoroquinolone, E = ethambutol. Coloured cells relate to individual drug scores on the ranking system, indicated in Table 3: green ≥ 12; orange 9 – 11; yellow < 9; red not currently manufactured.